... 1 (LAT-1) in clinical gastric cancer (GC) patients could predict patient therapeutic response to postoperative adjuvant chemotherapy. Methods: Immunohistochemistry was used to investigate LAT-1, CD98, and phosphorylated-mammalian target of rapamycin (p-mTOR) expression in 111 GC patients. To clarify...

... for oncotherapy remains unclear. Here we report that the synthesis of glycolytic and PPP enzymes is almost ubiquitously augmented in colorectal carcinoma (CRC) specimens. The mammalian target of rapamycin (mTOR) inhibitor INK128 (300 n M ) and phytochemical Avemar (1 mg/ml) inhibited the synthesis of PPP enzymes...

... is an attractive approach to improving the efficacy of current first-line chemotherapy. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway and its negative regulator phosphatase and tensin homologue gene (PTEN) play an important role in the carcinogenesis by regulating...

.... The mammalian target of rapamycin (mTOR), a ubiquitously expressed protein kinase and important regulator of cell growth and proliferation, is implicated in cell processes that lead to uncontrolled growth of cancer cells. mTOR inhibitors are effective against several cancer types, and emerging data support...

... specifically targeted against some of the pathways known to be involved in cancer cell growth, survival and invasion. In 2011, the mammalian target of rapamycin (mTOR) inhibitor everolimus and the tyrosine kinase inhibitor sunitinib were approved for the treatment of pancreatic NET. Clinical trials evaluating...